• Главная
  • NEW DAY MEDICINE
  • 10 (96) 2026
  • 95 -10 (96) 2026 - Alimov J.M. - KOMPLEKS DAVOLASHDAN KEYIN OG’IZ BO’SHLIG’I VA OG’IZ-HALQUM SARATONIDA FUNKSIONAL VA NUTRITIV BUZILISHLARNI TIKLASH: MODULLI INDIVIDUAL REABILITATSIYA DASTURINING NATIJALARI

95 -10 (96) 2026 - Alimov J.M. - KOMPLEKS DAVOLASHDAN KEYIN OG’IZ BO’SHLIG’I VA OG’IZ-HALQUM SARATONIDA FUNKSIONAL VA NUTRITIV BUZILISHLARNI TIKLASH: MODULLI INDIVIDUAL REABILITATSIYA DASTURINING NATIJALARI

KOMPLEKS DAVOLASHDAN KEYIN OG’IZ BO’SHLIG’I VA OG’IZ-HALQUM SARATONIDA FUNKSIONAL VA NUTRITIV BUZILISHLARNI TIKLASH: MODULLI INDIVIDUAL REABILITATSIYA DASTURINING NATIJALARI

Alimov J.M. - Samarqand davlat tibbiyot universiteti

Rezyume

Og’iz bo’shlig’i va og’iz-halqum saratoni bilan og’rigan bemorlarda o’smaga qarshi kompleks davodan keyin yuzaga keladigan funksional va nutritiv buzilishlarni tiklashda modulli individual reabilitatsiya dasturining samaradorligini standart reabilitatsiya bilan solishtirib baholash. Prospektiv qiyosiy tadqiqotda (2022–2026-yillar, “Akfa Medline” klinikasi) 110 nafar bemor ishtirok etdi. Asosiy guruh (n=60) sindromal-modulli yondashuv asosida shakllantirilgan dastur (“Disfagiya”, “Trizm”, “Nutq”, “Limfostaz va yelka kamari”, “Ovqatlanish” modullari) bo’yicha, taqqoslash guruhi (n=50) esa standart reabilitatsiya bo’yicha shug’ullandi. Nazorat guruhini 30 nafar amalda sog’lom shaxs tashkil qildi. Ko’rsatkichlar reabilitatsiya boshlanishidan oldin hamda 1, 3, 6 va 12 oy o’tgach baholandi (EAT-10, FOIS, og’izning maksimal ochilishi, nutq ravonligi, bo’yin aylanasi, VASH, goniometriya, tana vazni, NRS-2002, albumin). 12 oydan keyin asosiy guruhda EAT-10 balli 19,6±6,1 dan 3,8±3,1 gacha tushdi (taqqoslash guruhida — 8,7±4,4 gacha; p<0,001); to’liq peroral ovqatlanish (FOIS 7) bemorlarning 73,3 foizida tiklandi (taqqoslash guruhida — 46,0%). Og’iz ochilishi 27,8±6,4 mm dan 39,2±4,8 mm gacha kengaydi (taqqoslash guruhida — 34,5±5,2 mm; p<0,001), trizm esa 21,7% bemorda saqlanib qoldi (taqqoslash guruhida — 48,0%; p=0,003). Nutq tushunarliligi 90,6±7,8% ni (taqqoslash guruhida — 78,8±9,7%; p<0,001), limfostaz 16,7% ni (38,0%; p=0,016), VASH bo’yicha og’riq 1,3±1,0 ballni (2,6±1,3 ball; p<0,001) tashkil etdi. Ovqatlanish yetishmovchiligi xavfi (NRS-2002 ≥3) mavjud bemorlar ulushi 13,3% gacha kamaydi (taqqoslash guruhida — 32,0%; p=0,022). Yetakchi reabilitatsiya sindromlariga qarab tanlangan modulli dastur yutish, og’iz ochish, nutq, limfa oqimi va ovqatlanish funksiyalarini standart reabilitatsiyaga nisbatan to’liqroq tiklaydi. Guruhlar o’rtasidagi farqlar 3-oydan boshlab ishonchli bo’ladi va 12-oyga kelib yanada kuchayadi.

Kalit so’zlar: reabilitatsiya, og’iz bo’shlig’i saratoni, og’iz-halqum saratoni, disfagiya, trizm, limfostaz, nutritiv yordam.

First page

598

Last page

606

For citation:Alimov J.M. - KOMPLEKS DAVOLASHDAN KEYIN OG’IZ BO’SHLIG’I VA OG’IZ-HALQUM SARATONIDA FUNKSIONAL VA NUTRITIV BUZILISHLARNI TIKLASH: MODULLI INDIVIDUAL REABILITATSIYA DASTURINING NATIJALARI//New Day in Medicine 10(96)2026 598-606 https://newdayworldmedicine.com/en/new_day_medicine/10-96-2026

ADABIYOTLAR RO’YXATI

  1. Belafsky P.C., Mouadeb D.A., Rees C.J., et al. Validity and reliability of the Eating Assessment Tool (EAT-10). Ann Otol Rhinol Laryngol. 2008;117(12):919–924.
  2. Blyth K., Stainlay H., McCabe P. Speech and swallowing intervention following oral cancer treatment: a survey of speech-language pathologists in Australia and New Zealand. Int J Speech Lang Pathol. 2024;26(5):652–662. https://doi.org/10.1080/17549507.2023.2240043
  3. Borges M.M.F., Malta C.E.N., Ribeiro R.S., et al. Chemotherapy increases the prevalence of radiotherapy-related trismus in head and neck cancer patients: a systematic review and meta-analysis. J Clin Exp Dent. 2024;16(4)–e515. https://doi.org/10.4317/jced.61385
  4. Bray F., Laversanne M., Sung H., et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263.
  5. Crary M.A., Mann G.D., Groher M.E. Initial psychometric assessment of a functional oral intake scale for dysphagia in stroke patients. Arch Phys Med Rehabil. 2005;86(8):1516–1520.
  6. Deng J., Ridner S.H., Dietrich M.S., et al. Prevalence of secondary lymphedema in patients with head and neck cancer. J Pain Symptom Manage. 2012;43(2):244–252.
  7. Dijkstra P.U., Huisman P.M., Roodenburg J.L. Criteria for trismus in head and neck oncology. Int J Oral Maxillofac Surg. 2006;35(4):337–342.
  8. Gaitatzis K., Thompson B., Blake F.T., Koelmeyer L. Patient-reported outcome measures and physical function following head and neck lymphedema: a systematic review. J Cancer Surviv. 2026;20(2):738–751. https://doi.org/10.1007/s11764-024-01683-3
  9. Kondrup J., Rasmussen H.H., Hamberg O., Stanga Z. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr. 2003;22(3):321–336.
  10. Muscaritoli M., Arends J., Bachmann P., et al. ESPEN practical guideline: Clinical Nutrition in cancer. Clin Nutr. 2021;40(5):2898–2913.

    file

    download